SysVASC recognises Intellectual Property (IP) management as an important part of its work plan. To ensure effective collaboration across the entire consortium, a tailored plan for the protection of research results and exploitation of intellectual property rights arising within sysVASC has been developed.

SysVASC has a focus on market know-how, such as detailed similarity maps of animal models to human disease, or identified therapeutic targets as "business-to-business" products to pharmaceutical industry as first customers. The benefit to pharmaceutical industry customers will include access to know-how, sophisticated characterisation of animal models, detailed information on molecular features (potential therapeutic targets) associated with CVD far beyond currently established systems. This know-how might result in major advantages in drug development and (pre)clinical testing.


By continuing to use the site, you agree to the use of cookies. Privacy Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.